| Hazard Information | Back Directory | [Uses]
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. | [Mechanism of action]
Zolbetuximab is the first drug developed against the target of Claudin18.2. It is a chimeric IgG1 monoclonal antibody that specifically binds to Claudin18.2 on the surface of tumor cells, thereby triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis and inhibition of cell proliferation. | [in vivo]
Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
| Animal Model: | mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] | | Dosage: | 200 μg alone or with 50 mg/kg Gemcitabine | | Administration: | i.v.; i.p. (Gemcitabine) | | Result: | Inhibited tumor growth in two models, and prevented lung metastasis formation.
Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. |
|
|
| Company Name: |
Biolab Reagents Gold
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|